Clinically Significant Adverse Events from a Drug Interaction Between Quetiapine and Atazanavir‐Ritonavir in Two Patients

@article{Pollack2009ClinicallySA,
  title={Clinically Significant Adverse Events from a Drug Interaction Between Quetiapine and Atazanavir‐Ritonavir in Two Patients},
  author={T. Pollack and Christopher M McCoy and W. Stead},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2009},
  volume={29}
}
Clinicians caring for patients infected with the human immunodeficiency virus (HIV) and diagnosed with psychiatric comorbidities must be aware of potential drug‐drug interactions, particularly with protease inhibitor‐based antiretroviral therapy. Although possible interactions can be predicted based on a drug's pharmacokinetic parameters, the clinical significance is often unknown. We describe two patients who experienced serious quetiapine adverse effects potentially mediated through an… Expand
Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs
TLDR
This comprehensive review summarizes the currently available information regarding drug–drug interactions between antiretrovirals and pharmacologic agents utilized in the treatment of psychiatric disorders and provides recommendations for their management. Expand
Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs
TLDR
Recently published data on clinically significant drug interactions between ARVs and other drug classes including antineoplastics, immunosuppressant transplant drugs, directly acting antivirals for hepatitis C, antifungals, antimalarials, corticosteroids, psychotropics, hormonal contraceptives, anticoagulants, drugs for pulmonary hypertension, and herbal products are summarized. Expand
Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors
TLDR
The potential for CYP3A inhibition to contribute to adverse events related to HIV protease inhibitor–quetiapine coadministration and the frequency of concomitant use was estimated using literature review and physiologically based pharmacokinetic modeling. Expand
Clinical implications and management of drug-drug interactions between antiretroviral agents and psychotropic medications
TLDR
Some of the major drug interactions with antiretroviral agents used in the treatment of human immunodeficiency virus (HIV) are reviewed. Expand
Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy
Objective: To describe potential drug-drug interactions in the area of HIV/hepatitis C virus (HCV) coinfection and injection drug use, including those between antiretrovirals (ARVs), direct-actingExpand
Clinically Significant Drug Interactions with Atypical Antipsychotics
TLDR
Clinicians must be aware of the variety of factors that can increase the likelihood of clinically significant drug interactions with SGAs, and must carefully monitor patients to maximize treatment efficacy while minimizing adverse events. Expand
Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
TLDR
Clinicians prescribing antipsychotics should be aware of the likely risk of drug-drug interaction with COVID-19 medication and may benefit from taking into account present recommendations of use to preserve patient safety. Expand
Drug-Drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
TLDR
The main interaction between COVID-19 drugs and antipsychotics are the risk of QT prolongation and TdP, and CYP interactions. Expand
Drug Interactions of Psychiatric and COVID-19 Medications
TLDR
Psychiatric medication can be safely used in combination with COVID-19 pharmacotherapy with either a wise selection of medication with the least possibility of interaction or careful patient monitoring and management. Expand
Exposure to potentially dangerous drug-drug interactions involving antipsychotics.
TLDR
Interventions by physicians and pharmacies to reduce the prescribing and dispensing of potentially harmful pairs of medications to patients with schizophrenia are recommended. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 37 REFERENCES
Reversible Coma Caused By Risperidone-Ritonavir Interaction
TLDR
An HIV infected male admitted for manic behavior and treated with risperidone who developed a profound coma secondary to increased levels of ris peridone because of a possible drug interaction with ritonavir and indinavir is presented. Expand
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
TLDR
Dose adjustment need not be recommended for either methadone or atazanavir when co-administered to patients treated for opiate abuse and HIV disease and no clinically relevant pharmacokinetic interactions were found. Expand
Significant Interactions with New Antiretrovirals and Psychotropic Drugs
TLDR
Given the increasing use of multiple-drug therapy, the potential for drug interactions is extremely high and practitioners need to consider pharmacokinetic, pharmacologic, therapeutic, and adherence factors when managing interactions with complex antiretroviral therapy. Expand
Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir
TLDR
Short‐term low‐dose administration of ritonavir produces a large and significant impairment of triazolam clearance and enhancement of clinical effects, compared with the partial dependence of zolpidem clearance on CYP3A. Expand
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
TLDR
The large increase in the plasma concentrations of other protease inhibitors when coadministered with ritonavir forms the basis of rational dual protease inhibitor regimens, providing patients with 2 potent drugs at significantly reduced doses and less frequent dosage intervals. Expand
Extrapyramidal Symptoms with Ritonavir/Indinavir Plus Risperidone
TLDR
It is hypothesize that inhibition of CYP2D6 and CYP3A4 by ritonavir and indinavir may have resulted in an accumulation of the active moiety of risperidone, which may explain the occurrence of EPS in this patient. Expand
Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P‐Glycoprotein Activities
TLDR
Short‐term and steady‐state ritonavir effects on intestinal and hepatic CYP3A4/5 and P‐glycoprotein and liver function and on methadone pharmacokinetics and pharmacodynamics in healthy volunteers were determined. Expand
Quetiapine: a review of its safety in the management of schizophrenia.
TLDR
Quetiapine effectively treats both the positive and the negative symptoms of schizophrenia and is also associated with an incidence of extrapyramidal symptoms no greater than placebo across the entire dose range. Expand
Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels.
TLDR
It is hypothesized that the protease inhibitors' competition for binding to cytochrome P450 isoenzyme system CYP3A induced extreme prolongation of tacrolimus metabolism. Expand
Influence of Ritonavir on Olanzapine Pharmacokinetics in Healthy Volunteers
TLDR
Ritonavir significantly reduced the systemic exposure of olanzapine in volunteers and may ultimately require higher olanZapine doses to achieve desired therapeutic effects. Expand
...
1
2
3
4
...